相似文献
1
Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab.甲状旁腺功能减退：度伐利尤单抗治疗的一种罕见不良反应。
Endocr Oncol. 2022 Sep 22;2(1):K21-K24. doi: 10.1530/EO-22-0047. eCollection 2022 Jan.
2
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.免疫检查点抑制剂内分泌免疫相关不良事件的管理：最新综述
Endocr Connect. 2020 Oct;9(10):R207-R228. doi: 10.1530/EC-20-0342.
3
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.罕见内分泌免疫相关不良事件的未知领域
Cancers (Basel). 2023 Mar 28;15(7):2016. doi: 10.3390/cancers15072016.
4
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂引起的内分泌功能障碍的临床特征、管理和潜在生物标志物。
Endocrinol Metab (Seoul). 2021 Apr;36(2):312-321. doi: 10.3803/EnM.2021.1007. Epub 2021 Apr 27.
5
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.美国 FDA 批准的免疫检查点抑制剂的毒性负担模式。
J Exp Clin Cancer Res. 2023 Jan 5;42(1):4. doi: 10.1186/s13046-022-02568-y.
6
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.与免疫检查点抑制剂相关的内分泌相关不良事件：管理的建议算法。
Oncologist. 2020 Apr;25(4):290-300. doi: 10.1634/theoncologist.2018-0470. Epub 2019 Oct 10.
7
New insight in endocrine-related adverse events associated to immune checkpoint blockade.免疫检查点阻断相关内分泌不良事件的新认识。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
9
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.免疫检查点抑制剂相关的免疫相关不良事件：FDA 不良事件报告系统的更新综合比例失调分析。
Int Immunopharmacol. 2021 Jun;95:107498. doi: 10.1016/j.intimp.2021.107498. Epub 2021 Mar 13.
10
UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY.肿瘤免疫治疗中内分泌免疫相关不良事件的最新进展
Acta Endocrinol (Buchar). 2021 Apr-Jun;17(2):286-289. doi: 10.4183/aeb.2021.286.
引用本文的文献
1
Durvalumab-Induced Hypoparathyroidism.度伐利尤单抗诱导的甲状旁腺功能减退症。
AACE Endocrinol Diabetes. 2025 Apr 23;12(2):97-100. doi: 10.1016/j.aed.2025.04.005. eCollection 2025 Jul-Aug.
2
Hypoparathyroidism induced by immune checkpoint inhibitors: a review of literature reports and real-world pharmacovigilance data.免疫检查点抑制剂诱发的甲状旁腺功能减退：文献报道与真实世界药物警戒数据综述
Endocr Connect. 2025 Jul 12;14(7). doi: 10.1530/EC-25-0123. Print 2025 Jul 1.
3
An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review.免疫检查点抑制剂相关甲状旁腺功能减退症的一例极其罕见病例及文献综述
JCEM Case Rep. 2025 May 12;3(6):luaf097. doi: 10.1210/jcemcr/luaf097. eCollection 2025 Jun.
4
Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy.免疫检查点抑制剂治疗危及生命的内分泌免疫相关不良事件。
Cancers (Basel). 2023 Dec 10;15(24):5786. doi: 10.3390/cancers15245786.
本文引用的文献
1
Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.免疫检查点抑制剂治疗的器官特异性不良事件，特别提及内分泌病
touchREV Endocrinol. 2021 Apr;17(1):21-32. doi: 10.17925/EE.2021.17.1.21. Epub 2021 Apr 28.
2
Endocrine dysfunction induced by immune checkpoint inhibitors.免疫检查点抑制剂引起的内分泌功能障碍。
Medicina (B Aires). 2021;81(2):269-278.
3
Endocrine complications of immunotherapies: a review.免疫疗法的内分泌并发症：综述
Clin Med (Lond). 2021 Mar;21(2):e212-e222. doi: 10.7861/clinmed.2020-0827.
4
Understanding adverse events of immunotherapy: A mechanistic perspective.理解免疫治疗的不良反应：一种机制观点。
J Exp Med. 2021 Jan 4;218(1). doi: 10.1084/jem.20192179.
5
Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy.甲状旁腺功能减退症：一种与免疫检查点抑制剂治疗相关的罕见并发症。
Mayo Clin Proc Innov Qual Outcomes. 2020 Nov 3;4(6):821-825. doi: 10.1016/j.mayocpiqo.2020.07.006. eCollection 2020 Dec.
6
Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up.钙敏感受体自身抗体介导的免疫检查点抑制剂治疗相关性甲状旁腺功能减退症：诊断和长期随访。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000687.
7
Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗相关不良事件的诊断、监测和管理。
Curr Oncol. 2020 Apr;27(Suppl 2):S43-S50. doi: 10.3747/co.27.5111. Epub 2020 Apr 1.
8
Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism.免疫治疗引起的甲状旁腺功能减退症中钙敏感受体的激活抗体。
J Clin Endocrinol Metab. 2020 May 1;105(5). doi: 10.1210/clinem/dgaa092.
9
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.炎症诱导的甲状旁腺功能减退症由黑色素瘤的联合免疫检查点阻断引发。
J Immunother Cancer. 2019 Feb 21;7(1):52. doi: 10.1186/s40425-019-0528-x.
10
French Endocrine Society Guidance on endocrine side effects of immunotherapy.法国内分泌学会关于免疫治疗内分泌副作用的指南。
Endocr Relat Cancer. 2019 Feb;26(2):G1-G18. doi: 10.1530/ERC-18-0320.
Zotero 插件